MRG002

DRUG10 trials

Sponsors

Shanghai Miracogen Inc.

Conditions

Advanced Breast CancerAdvanced Solid TumorAdvanced Solid TumorsAdvanced or Metastatic Biliary Tract CancerAdvanced or Metastatic Breast CancerAdvanced or Metastatic Gastric CancerAdvanced or Metastatic Gastroesophageal Junction CancerAdvanced or Metastatic Urothelium Cancer

Phase 1

A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

Active, not recruitingNCT04492488

Shanghai Miracogen Inc.Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer, Advanced Solid Tumors

Start: 2021-05-24End: 2024-12-31Target: 129Updated: 2024-10-22

A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors

Shanghai Miracogen Inc.Advanced Solid Tumor

Start: 2018-11-21End: 2022-10-31Target: 74Updated: 2021-12-03

Phase 2

A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Shanghai Miracogen Inc.Advanced or Metastatic Breast Cancer

Start: 2021-05-13End: 2023-02-28Target: 66Updated: 2022-09-07

A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Shanghai Miracogen Inc.Advanced or Metastatic Biliary Tract Cancer

Start: 2021-06-07End: 2023-08-31Target: 86Updated: 2021-12-10

A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

Shanghai Miracogen Inc.Locally Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma

Start: 2021-04-20End: 2022-09-30Target: 58Updated: 2021-12-14

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Shanghai Miracogen Inc.Advanced Breast Cancer, Metastatic Breast Cancer

Start: 2021-06-30End: 2023-10-31Target: 350Updated: 2023-03-17

A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).

Shanghai Miracogen Inc.Non-small- Cell Lung Cancer (NSCLC)

Start: 2021-12-31End: 2023-12-31Target: 100Updated: 2021-12-02

A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.

Shanghai Miracogen Inc.Locally Advanced Gastric Cancer, Metastatic HER2 Positive Gastroesophageal Junction Cancer

Start: 2022-01-19End: 2023-12-31Target: 60Updated: 2022-02-23

A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

Shanghai Miracogen Inc.Breast Cancer With Liver Metastases

Start: 2022-03-23End: 2023-10-31Target: 99Updated: 2022-12-02

Phase 3

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

RecruitingNCT05754853

Shanghai Miracogen Inc.Advanced or Metastatic Urothelium Cancer

Start: 2023-04-06End: 2027-01-31Target: 290Updated: 2023-04-13

Related Papers

Abstract P4-12-21: Efficacy and Safety of MRG002 in Prior TKI-Treated HER2 Positive Breast Cancer Patients: A Single Arm, Open Label, Multicenter, Phase II Study

Clinical Cancer Research2025-06-13

A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer.

Journal of Clinical Oncology2022-06-0136 citations

MRG002-006: A multicenter phase II clinical trial of MRG002-ADC for unresectable locally advanced or metastatic urothelial cancer.

Journal of Clinical Oncology2022-06-017 citations